Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562972 | 0.77 | CYP2D6 (0.41) | CYP2D6CA1CA7CA2HDAC3 | |
| SCHEMBL4338603 | 0.75 | CYP2D6 (0.34) | CYP2D6CA12CA14CA1CA7 | |
| SCHEMBL5577164 | 0.75 | CYP2D6 (0.39) | CYP2D6CA12CA14CA1CA7 | |
| SCHEMBL13981283 | 0.73 | CYP2D6 (0.38) | CYP2D6CA12CA14CA1CA7 | |
| SCHEMBL491209 | 0.72 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL7428898 | 0.72 | CYP2D6 (0.44) | CYP2D6CA12CA14CA1CA7 | |
| SCHEMBL19199788 | 0.72 | MEN1 (0.36) | CYP2D6CA12CA14CA1CA7 | |
| SCHEMBL4333800 | 0.71 | CYP2D6 (0.35) | CYP2D6CA1CA7CA2 | |
| SCHEMBL4347578 | 0.70 | CYP2D6 (0.33) | CYP2D6CA1CA7CA2 | |
| SCHEMBL4332980 | 0.70 | CYP2D6 (0.33) | CYP2D6CA1CA7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | ANORMED INC. (CA) | 2002-04-25 | — | — | US | disclosed |
| EP-1163247-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056743-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | CFD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12 | CYP2D6 53/4885CA12 198/4885CA14 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.